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Conclusions" Quantitative and qualitative methods of assessing 
change in response to an intervention for knee OA have shown 
worrying differences. It is unlikely that these can be explained by 
the rather different timing of the two assessments. The context 
and way in which responses are elicited may make a big differ- 
ence to reported outcomes in OA. 
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Aim: To assess change in pain and disability status, and factors 
influencing such changes, amongst a population based sample 
with osteoarthritis of the hip and/or knee. 
Methods: Individuals in the Somerset and Avon Survey of Health 
(SASH) who reported knee/hip pain were assigned New Zealand 
(NZ) scores between 1992 and 1994. Respondents were followed 
up (25% random sample, n=587) between 1998 and 1999, when 
the NZ score was repeated (minus the clinical component). 
Separate analyses were conducted for knees and hips, with the 
worse joint at follow-up used as the index joint for analysis of 
change. Adjusting for baseline score, age, sex and surgery, vari- 
ous potential predictors were considered for the follow-up score 
using univariate and multivariable r gression. 
Results: Response rate was 66% (n=390). For knees, the mean 
score at baseline of 21.4 (95% CI 19.6, 23.2, n=283) had wors- 
ened at follow-up, to 28.5 (CI 26.3, 30.6). Corresponding figures 
for hips were 21.8 (C119.2, 24.5: n=204), and 27.2 (CI 24.8, 29.7). 
For knees, women had deteriorated to a greater degree than men 
(p=0.05). Older age groups had worse scores at baseline and fol- 
low-up, and deteriorated to a greater degree than younger age 
groups (p=0.004). The age differences were greater for women 
than for men (p=0.009). Multivadable analysis found that the fol- 
lowing variables were independently associated with change in 
NZ score for knees: employment status (p=0.006), social class 
(p=0.009), hypertension (p=0.03), and having consulted a com- 
munity doctor between baseline and follow-up (p<0.0001). For 
hips, there were several univariate associations, but these did not 
remain in multivariable analysis. 
Conclusions: The NZ score appears to be sensitive to change in 
pain and disability status. Age and gender differences support 
findings of previous research. The association between change in 
knee score and hyper-tension may be confounded by BMI (cur- 
rently being explored). Associations with employment status and 
social class indicate that both these aspects have consequences 
for the prograssion of OA symptoms. 
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Rationale: Viscosupplementation with Hylan GF-20 is widely 
used in the treatment of knee osteoarthritis (OA) but predictive 
factors of its efficacy have not been yet fully demonstrated. 
Aim: To determine the predictive factors of long term efficacy of
viscosupplementation by Hylan GF-20 in patients with knee 0A. 
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Patients and methods: 155 patients (80 women, 75 men, mean 
age 69, mean disease duration 6 years, mean BMI 27.9) were 
questioned, using a standardized questionnaire, about the effica- 
cy and the satisfaction towards the treatment, 7 and 14 months 
after 3 injections of Hylan GF-20 for knee OA (ACR criteria). 
Radiological grade of OA (Kellgren and Lawrence-KL), topogra- 
phy of joint space narrowing (tibiofemoral, patello femoral or 
global), way of injection (anterior, superolateral or superomedial 
routes), synovial fluid (SF) volume (absent, mild, or important if 
effusion during treatment), and adverse events were collected. 
Logistic regressions, taking into account age, sex, BMI, and time 
between treatment and interview, were performed to determine 
the predictive factors of efficacy of the treatment. 
Results: Safety was considered as excellent or good in 96.2% of 
the cases. At month 7 and 14 the percentage of patients atisfied 
with the treatment was respectively 77.9% and 48.5%. Factors 
associated with good efficacy of the treatment (p<0.05) were: 
presence of a mild SF effusion (OR 6.9), tibiofemoral joint space 
narrowing (OR 2.68), radiological calcinosis of the meniscus (OR 
1 3.3) lateral and medial mutes of injection (OR 2.59), and KL 
grade IV (OR 9.2). 
Conclusion: The study demonstrates that several factors are 
strongly associated with good response to visco supplementa- 
tion therapy in patients suffering from knee OA. These data could 
be helpful to select patients who may derive benefit from visco- 
supplementation therapy. 
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Objective: It was intended to compare the fficacy and safety of 
an oral enzyme-rutosid combination (ERC), containing rutosid 
and the enzymes bromelain and trypsin, with that of dictofenac in 
patients with osteoarthritis of the knee, based on the meta-analy- 
sis of three studies. 
Methods: For the meta-analysis three double-blind randomized 
controlled clinical trials comparing the fficacy and safety of ERC 
with that of diclofenac in patients with osteoarthritis of the knee 
were available. The trials had been performed according to iden- 
tical study protocols, but due to small sample sizes sufficient evi- 
dence of the study objectives could not be achieved. Pooling of 
the studies lead to an adequate sample size of 195 patients. Re- 
analyses of the individual studies were restricted to the primary 
study criteria Lequesne's algofunctional index and the sum score 
of a complaint index, in order to demonstrate quivalent efficacy 
of ERC and diclofenac. First line analysis was performed with the 
Wilcoxon-Mann-Whitney procedure, testing the two primary cri- 
teria in sequential order. In addition a summarizing analysis of all 
efficacy criteria was performed, using the directional non-para- 
metric test of the efficient Wei-Lachin procedure. For the purpose 
of meta-analysis, results were combihed by stratified pooling 
procedures--weighted and semi-weighted pooling of measures. 
Results: individual analyses of the three studies gave evidence 
for equivalent efficacy of both treatments. The meta-analysis 
demonstrated very good evidence that after 3 weeks of treatment 
ERC is at least as effective as diclofenac in achieving both, 
improved knee function and decrease of pain. 
Conclusions: ERC may be considered as a valuable alternative 
to nonsteroidal anti-inflammatory drugs (NSAID) in the treatment 
of patients with osteoarthritis of the knee. This is the more so in 
situations where, due to the patient's history, the physician is 
reluctant o prescribe NSAID. 
